Evotec AG announced today that its multi-target endometriosis alliance with Bayer has advanced a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-bayer-advance-endometriosis-programme-into-phase-i-clinical-development-and-extend-alliance-5478